CMS Launches Temporary Demonstration Program Beginning July 1
This July, Medicare beneficiaries seeking GLP-1 medications for weight loss will have a clearer path to coverage. Although Medicare covers GLP-1 medications for certain medical conditions (like Type 2 diabetes and obstructive sleep apnea), it does not cover drugs for weight management purposes.
That long-standing restriction remains in federal law. However, the Centers for Medicare & Medicaid Services (CMS) introduced a new demonstration initiative that expands access to eligible beneficiaries. Known as the Medicare GLP-1 Bridge, the program officially begins on July 1, 2026.
A Temporary Pathway to Weight-Loss Coverage
CMS announced the Medicare GLP-1 Bridge on December 23, 2025, as a temporary demonstration project. It’s purpose is to help beneficiaries obtain coverage for certain GLP-1 weight-loss medications when those drugs are not otherwise covered through their prescription drug (Part D) plans.
The initiative will operate from July 1, 2026, through December 31, 2027.
How Much Will I Pay for Weight-Loss Drugs Under the GLP-1 Bridge?
Unlike traditional prescription drug coverage, the Medicare GLP-1 Bridge functions independently of Medicare Part D. Drug plans do not administer the benefit, assume financial risk, or decide whether to participate. Instead, CMS oversees the program through a centralized administrative system.
Beneficiaries who qualify will pay a flat copayment of $50 per prescription fill. Because the benefit exists outside Part D, those payments do not count toward deductibles or true out-of-pocket spending calculations.
Who Is Eligible?
Eligibility is designed primarily for Medicare beneficiaries who cannot obtain GLP-1 coverage for weight management through their existing prescription drug plan.
To participate, individuals must meet both plan-related and clinical requirements established by CMS.
A healthcare provider must certify that the patient:
- Is at least 18 years old.
- Is receiving the medication specifically for weight management.
- Meets CMS-established body mass index (BMI) requirements.
An important detail is that CMS evaluates BMI eligibility based on the patient’s weight and BMI when GLP-1 treatment originally began—not necessarily at the time of the authorization request. As a result, beneficiaries who have already lost weight while using a GLP-1 medication may still qualify if they met the required BMI threshold when treatment started.
Certain Medical Conditions Exclude Participation
Not everyone seeking a GLP-1 medication will qualify for the Bridge program.
Individuals diagnosed with Type 2 diabetes, moderate-to-severe obstructive sleep apnea, or non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced liver fibrosis are excluded from the demonstration. Those who have cardiovascular disease and take GLP-1’s to manage cardiovascular risk are also excluded from the program.
Which Drugs Are Included?
CMS has identified three GLP-1 products that may be covered through the demonstration:
- Foundayo (oral tablet)
- Wegovy (including approved formulations)
- Zepbound (KwikPen presentation)
Coverage applies only when these medications are prescribed for reducing excess body weight and supporting long-term weight management. Prescriptions written for other FDA-approved uses must be processed through standard Medicare Part D channels.
Understanding the Costs
Beneficiaries enrolled in the program will pay a fixed $50 copayment for each prescription fill, regardless of income status or eligibility for Medicare’s Low-Income Subsidy program.
Several important financial rules apply:
- The copayment does not count toward Part D deductibles.
- It does not apply to true out-of-pocket spending totals.
- It cannot be included under the Medicare Prescription Payment Plan.
- Manufacturer coupons and discount assistance programs cannot be used.
CMS has established a separate payment arrangement with participating manufacturers and pharmacies to support the demonstration.
Looking Ahead
The Medicare GLP-1 Bridge creates a new opportunity for eligible beneficiaries to access certain weight-loss medications. Over the next 18 months, utilization trends, patient outcomes, and program costs could play a significant role in shaping how Medicare approaches GLP-1 coverage in the future.
Beneficiaries interested in the program should speak with their healthcare provider to determine whether they meet eligibility requirements and whether a GLP-1 medication may be appropriate for their situation.
Medical establishment , schools, were quiet on the obesity amongst children and adults, and now that very same establishment will introduce the drug, not the self discipline, change in menu, portions and eating habits, not getting off the couch but drugs, how sick are we, there were excuses for obesity , everything but personal responsibility and life style change. Sick.